Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript
Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.7, indicating a -1.14% shift from the previous trading day.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) reached $0.68 at the closing of the latest trading day, reflecting a -7.13% change compared to its last close.
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.61, marking a -6.63% move from the previous day.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.59, representing a -2.44% change from its previous close.
Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript
Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.
